141 related articles for article (PubMed ID: 34227400)
1. Real-world treatment patterns and effectiveness outcomes in patients with early-stage triple-negative breast cancer.
Haiderali A; Rhodes WC; Gautam S; Huang M; Sieluk J; Skinner KE; Schwartzberg LS
Future Oncol; 2021 Oct; 17(29):3819-3831. PubMed ID: 34227400
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource utilization and cost among patients treated for early-stage triple-negative breast cancer.
Haiderali A; Rhodes WC; Gautam S; Huang M; Sieluk J; Skinner KE; Schwartzberg LS
Future Oncol; 2021 Oct; 17(29):3833-3841. PubMed ID: 34254533
[TBL] [Abstract][Full Text] [Related]
3. Association between event-free survival and overall survival in early-stage triple-negative breast cancer.
Huang M; Fasching PA; Haiderali A; Xue W; Pan W; Karantza V; Yang F; Truscott J; Xin Y; O'Shaughnessy J
Future Oncol; 2024 Feb; 20(6):335-348. PubMed ID: 37602372
[No Abstract] [Full Text] [Related]
4. Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.
Gass P; Lux MP; Rauh C; Hein A; Bani MR; Fiessler C; Hartmann A; Häberle L; Pretscher J; Erber R; Wachter DL; Schulz-Wendtland R; Beckmann MW; Fasching PA; Wunderle M
BMC Cancer; 2018 Oct; 18(1):1051. PubMed ID: 30373556
[TBL] [Abstract][Full Text] [Related]
5. Real-world outcomes in metastatic HR+/HER2-, HER2+ and triple negative breast cancer after start of first-line therapy.
W DeClue R; Fisher MD; Gooden K; Walker MS; Le TK
Future Oncol; 2023 Apr; 19(13):909-923. PubMed ID: 37191097
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns, healthcare resource utilization and outcomes for early stage triple-negative breast cancer in Japan.
Sanno H; Taniguchi K; Yoshimoto Y; Saji S
Future Oncol; 2024 Apr; 20(13):833-849. PubMed ID: 38305038
[TBL] [Abstract][Full Text] [Related]
7. Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis.
Huang M; O'Shaughnessy J; Zhao J; Haiderali A; Cortés J; Ramsey SD; Briggs A; Hu P; Karantza V; Aktan G; Qi CZ; Gu C; Xie J; Yuan M; Cook J; Untch M; Schmid P; Fasching PA
Cancer Res; 2020 Dec; 80(24):5427-5434. PubMed ID: 32928917
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Response and Survival Outcomes of Triple Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
Zhu M; Yu Y; Shao X; Zhu L; Wang L
Chemotherapy; 2020; 65(3-4):101-109. PubMed ID: 32894832
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
Gamucci T; Pizzuti L; Sperduti I; Mentuccia L; Vaccaro A; Moscetti L; Marchetti P; Carbognin L; Michelotti A; Iezzi L; Cassano A; Grassadonia A; Astone A; Botticelli A; Magnolfi E; Di Lauro L; Sergi D; Fuso P; Tinari N; Barba M; Maugeri-Saccà M; Landucci E; Conti F; Sanguineti G; De Tursi M; Iafrate G; Giordano A; Ciliberto G; Natoli C; Vici P
J Cell Physiol; 2018 Mar; 233(3):2313-2323. PubMed ID: 28710865
[TBL] [Abstract][Full Text] [Related]
11. Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer.
Kolberg HC; Loevey G; Akpolat-Basci L; Stephanou M; Fasching PA; Untch M; Bulsara M; Vaidya JS; Liedtke C
Rev Recent Clin Trials; 2017; 12(2):93-100. PubMed ID: 28155607
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Triple-Negative Breast Cancers (TNBC) Compared with Non-TNBC: Does the Survival Vary for All Stages?
Agarwal G; Nanda G; Lal P; Mishra A; Agarwal A; Agrawal V; Krishnani N
World J Surg; 2016 Jun; 40(6):1362-72. PubMed ID: 26842691
[TBL] [Abstract][Full Text] [Related]
13. Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from Turkey.
Budakoglu B; Altundag K; Aksoy S; Kaplan MA; Ozdemir NY; Berk V; Ozkan M; Algin E; Kandemir N; Dogu GG; Harputluoglu H; Arslan UY; Coskun U; Isikdogan A; Oksuzoglu B
J BUON; 2014; 19(4):872-8. PubMed ID: 25536589
[TBL] [Abstract][Full Text] [Related]
14. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
15. Temporal Variation of Treatment Patterns and Survival Outcomes of Triple-Negative Breast Cancer Patients: A Real-World Experience From 2000 to 2014.
Valcarcel B; Torres-Roman JS; Enriquez D; Vidaurre T; De la Cruz-Ku G
Clin Breast Cancer; 2023 Oct; 23(7):737-745.e5. PubMed ID: 37507258
[TBL] [Abstract][Full Text] [Related]
16. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
17. Early triple-negative breast cancer in women aged ≥65: retrospective study of outcomes, resource use and costs, 2010-2016.
Sieluk J; Haiderali A; Huang M; Yang L; Hirshfield KM
Future Oncol; 2021 Mar; 17(9):1039-1054. PubMed ID: 33261515
[No Abstract] [Full Text] [Related]
18. Breast cancer subtypes can be a predictor of pathologic complete response and survival in the neoadjuvant setting for T4 noninflammatory breast cancer.
Gülben K; Berberoğlu U; Kinaş V; Başkan E
Acta Chir Belg; 2014; 114(3):153-9. PubMed ID: 25102703
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology.
Jung HA; Park YH; Kim M; Kim S; Chang WJ; Choi MK; Hong JY; Kim SW; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
Tumour Biol; 2015 Feb; 36(2):1073-9. PubMed ID: 25326808
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
